Skip to main content
Equibles

ZYDUSLIFE · Zydus Lifesciences Limited · Documents

Use ZYDUSLIFE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZYDUSLIFE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,191.00 INR -14.50 (-1.20%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 29.01K Avg daily vol (3M) 103.01K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 4, 2026
2026
Nov 4
Earnings call
Revenue rises 29% as Saroglitazar launch nears

Zydus Lifesciences reported second-quarter revenues of ₹79.1 billion, up 29% year-on-year, and a 24% EBITDA margin. It expects a March Saroglitazar launch and maintained full-year EBITDA margin guidance of 24%.

4 source passages
We registered consolidated revenues of ₹79.1 billion, up 29% on a year-on-year basis. Our operating profitability remained robust with an EBITDA margin of 24% despite continued investments towards Saroglitazar launch related activities in the US. So, November is our current goal date and we are, as I said, our current expectation is to launch in March. Yes, we maintain that guidance of 24% EBITDA margin for the full year. Open the document at this passage
Showing 1–2 of 2 documents